Zobrazeno 1 - 10
of 99
pro vyhledávání: '"S. V. Sharov"'
Autor:
A. I. Stukan, A. Yu. Goryainova, O. Yu. Chukhray, S. D. Maksimenko, E. N. Imyanitov, S. V. Sharov, Z. K. Khachmamuk
Publikováno v:
Опухоли женской репродуктивной системы, Vol 18, Iss 2, Pp 29-39 (2022)
Background. It is suggested that defects in BRCA1 / 2 genes contribute to a high mutational load and high immunogenicity, which modulates immune microenvironment. At the same time, it was shown that BRCA1 / 2-associated breast cancer tumors do not be
Externí odkaz:
https://doaj.org/article/4e05972ed359486aa02e998a9edcecef
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 40-48 (2022)
Introduction. Cyclin-dependent kinase 4/6 inhibitors are indicated in endocrine therapy for the treatment of hormone receptorpositive, HER2-negative, advanced, or metastatic breast cancer. In the recent past, abemaciclib made its debut as a combinato
Externí odkaz:
https://doaj.org/article/b70ac2cf7e864264baeba4fe71f69b7b
Autor:
A. I. Stukan, A. Yu. Goryainova, S. V. Sharov, O. A. Goncharova, Z. K. Khachmamuk, V. V. Durov
Publikováno v:
Опухоли женской репродуктивной системы, Vol 18, Iss 1, Pp 54-65 (2022)
PARP inhibitors. However, in clinical practice, despite the proven antitumor efficacy of drugs, acquired resistance to PARP inhibitors leads to difficulties in selecting further therapy due unknown resistance mechanisms and absence of algorithm of ac
Externí odkaz:
https://doaj.org/article/7d2c92eff3024fb38d7c8a2b41469daa
Autor:
A. I. Stukan, A. Yu. Goryainova, A. A. Meshcheryakov, V. A. Porkhanov, R. A. Murashko, S. V. Sharov, V. N. Bodnya
Publikováno v:
Бюллетень сибирской медицины, Vol 21, Iss 1, Pp 171-182 (2022)
Activation of the estrogen receptor-α (ER-α) signaling pathway is a significant factor in the initiation of carcinogenesis in various types of tumors due to the genomic and non-genomic effects of estradiol in cancer cells. However, data on the expr
Externí odkaz:
https://doaj.org/article/537f72280566413aaba4f8195bc60c8c
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 25-34 (2021)
Influencing the pre-metastatic niche is a very perspective cancer treatment strategy in order of preventing metastases formation. It was found that bone marrow progenitor cells and tumor cells secreting biological compounds are key components in the
Externí odkaz:
https://doaj.org/article/244ee19ad8b84ee6901795ba2aa7c743
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 84-93 (2021)
Hepatocellular carcinoma is one of the most formidable and deadly cancers. The limited possibilities of surgical methods of treatment as well as the formation of multiple drug resistance caused by the biological characteristics of both the liver tiss
Externí odkaz:
https://doaj.org/article/4c5dfc1c054040c39682384a3dec846f
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 54-61 (2021)
The problem of metastatic breast cancer treatment is linked with clonal selection both in the process of tumor evolution and under the influence of previous treatment. The analysis of metastatic niche microenvironment and the molecular genetic featur
Externí odkaz:
https://doaj.org/article/946ad29af7c647c3af1ecdd024e2de87
Autor:
E. A. Pasechnikova, V. N. Bodnya, S. V. Sharov, D. V. Kadomtsev, A. Y. Georgieva, A. I. Stukan
Publikováno v:
Инновационная медицина Кубани, Vol 0, Iss 3, Pp 57-63 (2021)
Background Liquid biopsy is a promising method of diagnosing malignant tumors. It allows determining the level of free circulating tumor cells – micrometastases, tumor DNA, microRNA and exosomes in blood plasma, as well as detecting various genetic
Externí odkaz:
https://doaj.org/article/178428cd8fd4409bb3a3aef76d46b0d6
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 138-146 (2021)
Metastatic breast cancer occupies a leading position in the structure of mortality among women with oncological diseases worldwide. At the same time, the control of metastatic disease remains a significant problem for clinical oncology despite the im
Externí odkaz:
https://doaj.org/article/63409ceede9a4531b8c9baa8ea69ead4
Publikováno v:
Медицинский совет, Vol 0, Iss 4S, Pp 25-32 (2021)
The treatment of advanced hormone- receptor-positive (HR+) breast cancer (BC) is a rather difficult task due to the emergence of resistance to the standard treatment regimen – endocrine therapy. This circumstance has led to the investigation of the
Externí odkaz:
https://doaj.org/article/1fb6731b55b1494aa175fe1790b60dd6